VALTRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H30O8
Molecular Weight	422.4688
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12[C@H](OC(=O)CC(C)C)OC=C(COC(C)=O)C1=C[C@H](OC(=O)CC(C)C)[C@]23CO3

InChI

InChIKey=BDIAUFOIMFAIPU-KVJIRVJXSA-N

InChI=1S/C22H30O8/c1-12(2)6-18(24)29-17-8-16-15(9-26-14(5)23)10-27-21(20(16)22(17)11-28-22)30-19(25)7-13(3)4/h8,10,12-13,17,20-21H,6-7,9,11H2,1-5H3/t17-,20+,21-,22+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H30O8
Molecular Weight	422.4688
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30638055 | https://www.ncbi.nlm.nih.gov/pubmed/24782906

Valtrate is a principle compound isolated from Valeriana jatamansi Jones, which is a Traditional Chinese Medicine used to treat various mood disorders. Valtrate at a high dose has been found to have sedative properties by inhibiting spontaneous motion and increasing the sleeping number induced by pentobarbital sodium in mice. In rats valtrate exhibits anxiolytic-like profiles in the elevated plus maze test and the open field test. Valtrate attenuated HPA axis activity by reducing the corticosterone level. Valtrate also possesses anti-breast cancer activities via cell cycle arrest, apoptosis, and inhibition of cell migration, thus supporting valtrate as a potential antitumor agent.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Exportin-1 8 Target ID: O14980 Gene ID: 7514.0 Gene Symbol: XPO1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25476752	Inhibitor 8297
Sodium/potassium-transporting ATPase subunit alpha-1 16 Target ID: P05023\|\|\|Q9UJ20 Gene ID: 476.0 Gene Symbol: ATP1A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21567360	Inhibitor 8297	21.2 µM [IC50]
Sodium/potassium-transporting ATPase 39 Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21567360	Inhibitor 8297	19.4 µM [IC50]

PubMed

Title	Date	PubMed
Concise synthesis of 5,6-dihydrovaltrate leading to enhanced Rev-export inhibitory congener.	2010 Aug 15	20643553

Sample Use Guides

In Vivo Use Guide

Rats were orally administered valtrate (5, 10, and 20 g/kg daily) for 10 days and exposed to open field test (OFT) and elevated plus-maze (EPM). Valtrate (10 mg/kg, p.o.) exhibited the anxiolytic effect in rats by increasing the time and entry percentage into the open arms in the EPM and the number of central entries in the OFT. Valtrate (10 mg/kg, p.o.) significantly reduced the corticosterone level in the rat serum.

Route of Administration: Oral

In Vitro Use Guide

Valtrate (100 uM) inhibited roughly half of the total H⁺/K⁺-ATPase activity from rat gastric epithelium (valtrate 54.6 ± 3.2 %). Valtrate showed the highest inhibitory potency toward Na⁺/K⁺-ATPase, and the inhibition curves obtained provided a similar IC₅₀ for rat kidney α1 isoform (21.2 uM) and brain hemispheres α2/ α3 isoforms (19.4 uM).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:50:41 GMT 2023` Edited by `admin` on `Fri Dec 15 16:50:41 GMT 2023`
Record UNII	L3JQ035X9B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VALTRATE

Official Name

English

Valtrate [WHO-DD]

Common Name

English

BUTANOIC ACID, 3-METHYL-, 4-((ACETYLOXY)METHYL)-6,7A-DIHYDROSPIRO(CYCLOPENTA-(C)PYRAN-7(1H),2'-OXIRANE)-1,6-DIYL ESTER, (1S-(1-.ALPHA.,6-.ALPHA,,7- .BETA.,7A-.ALPHA.))-

Common Name

English

VALEPOTRIATE

Common Name

English

VALTRATE [MART.]

Common Name

English

valtrate [INN]

Common Name

English

HALAZUCHROME B

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29756